Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma

Omran Saifi; William G Breen; William G Rule; Yi Lin; Javier Munoz; Mohamed A Kharfan-Dabaja; Jennifer L Peterson

doi:10.1001/jamaoncol.2024.1113

Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma

JAMA Oncol. 2024 May 9:e241113. doi: 10.1001/jamaoncol.2024.1113. Online ahead of print.

Authors

Omran Saifi¹, William G Breen², William G Rule³, Yi Lin^{4

5}, Javier Munoz⁶, Mohamed A Kharfan-Dabaja⁷, Jennifer L Peterson¹

Affiliations

¹ Department of Radiation Oncology, Mayo Clinic Jacksonville, Jacksonville, Florida.
² Department of Radiation Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
³ Department of Radiation Oncology, Mayo Clinic Phoenix, Phoenix, Arizona.
⁴ Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota.
⁵ Division of Experimental Pathology, Mayo Clinic Rochester, Rochester, Minnesota.
⁶ Division of Hematology, Mayo Clinic Phoenix, Phoenix, Arizona.
⁷ Division of Hematology, Mayo Clinic Jacksonville, Jacksonville, Florida.

PMID: 38722652
PMCID: PMC11082747 (available on 2025-05-09)
DOI: 10.1001/jamaoncol.2024.1113

No abstract available

Plain language summary

This cohort study examines the role of comprehensive bridging radiotherapy in the setting of chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.